Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

Pfizer's robust R&D pipeline is expected to drive future growth and offset patent expirations. Read why I maintain my buy ...

Atomwise, a leader in leveraging machine learning and artificial intelligence (ML/AI) to advance small molecule drug discovery, today announced the appointment of Steve Worland, Ph.D. as Chief ...

Despite a recently-agreed $7.4 billion settlement, the Sackler family has yet to fully account for its role in America's ...

Manufacturers of medicines, including Pfizer and Eli Lilly, have spent a combined $450,000 lobbying against price caps on ...

Taho Pharmaceuticals’s apixaban-based oral dissolving strips were discovered to be a bioequivalent of Pfizer and ...

The best way to beat persistent inflation is to invest in businesses unaffected by rising prices, like these four high-yield ...

Pfizer (NYSE: PFE) has been around for 175 years, but the company's revenue soared to its highest ever only in more recent ...

Pfizer (PFE) is a pharmaceutical and biotechnology company valued at $145 billion by market capitalization. While the company ...

A Fond du Lac woman is suing Pfizer and others over a brain tumor, arguing it’s associated with Depo-Provera, a form of birth ...

Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...

Medicare changes will cut $1 billion from 2025 revenue, with Pfizer now responsible for 20% of catastrophic drug costs. Read ...